Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting
Authors
Keywords
Cancer treatment, Hepatocellular carcinoma, Cost-effectiveness analysis, Chemotherapy, Cirrhosis, Cancer detection and diagnosis, HIV diagnosis and management, Palliative care
Journal
PLoS One
Volume 12, Issue 10, Pages e0185198
Publisher
Public Library of Science (PLoS)
Online
2017-10-11
DOI
10.1371/journal.pone.0185198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002–2009: a population-based cohort study
- (2016) H.H. Thein et al. Current Oncology
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Health State Utilities and Quality of Life in Patients with Hepatitis B
- (2016) Gloria Woo et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
- (2015) Pengfei Zhang et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Hepatocellular Carcinoma: Consensus, Controversies and Future Directions: A Report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting
- (2015) Kelly Warren Burak et al. Canadian Journal of Gastroenterology and Hepatology
- Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study
- (2015) Hla-Hla Thein et al. PLoS One
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
- (2014) Qi-Han Fu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma
- (2014) L. Vadot et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
- (2014) Leida Zhang et al. PLoS One
- An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma
- (2014) Songlin Peng et al. PLoS One
- Multidisciplinary approach for HCC patients: hepatology for the oncologists
- (2013) C. Barone et al. ANNALS OF ONCOLOGY
- Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
- (2013) Calogero Cammà et al. HEPATOLOGY
- Health care costs associated with hepatocellular carcinoma: A population-based study
- (2013) Hla-Hla Thein et al. HEPATOLOGY
- Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma
- (2013) Alessandro Cucchetti et al. JOURNAL OF HEPATOLOGY
- Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
- (2013) Gwang Hyeon Choi et al. RADIOLOGY
- Transarterial Chemoembolization Treatment: Association between Multiple Treatments, Cumulative Expenditures, and Survival
- (2013) Ian M. Breunig et al. VALUE IN HEALTH
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990–2009
- (2012) Nathaniel Jembere et al. PLoS One
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection
- (2011) Priscilla C Hsu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems
- (2010) C. CAMMÀ et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Economic evaluation of sorafenib in unresectable hepatocellular carcinoma
- (2010) Brian I. Carr et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada
- (2008) Noemi Muszbek et al. CURRENT MEDICAL RESEARCH AND OPINION
- Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review
- (2008) David J. McLernon et al. MEDICAL DECISION MAKING
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons
- (2008) Adrian R. Levy et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started